Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Receivables (2021 - 2025)

Tg Therapeutics has reported Change in Receivables over the past 5 years, most recently at $40.2 million for Q4 2025.

  • Quarterly results put Change in Receivables at $40.2 million for Q4 2025, up 199.03% from a year ago — trailing twelve months through Dec 2025 was $176.4 million (up 125.94% YoY), and the annual figure for FY2025 was $176.4 million, up 125.94%.
  • Change in Receivables for Q4 2025 was $40.2 million at Tg Therapeutics, up from $33.9 million in the prior quarter.
  • Over the last five years, Change in Receivables for TGTX hit a ceiling of $60.9 million in Q1 2025 and a floor of -$814000.0 in Q2 2022.
  • Median Change in Receivables over the past 5 years was $11.8 million (2023), compared with a mean of $16.1 million.
  • Biggest five-year swings in Change in Receivables: plummeted 608.75% in 2022 and later surged 24913.64% in 2023.
  • Tg Therapeutics' Change in Receivables stood at $5000.0 in 2021, then crashed by 1860.0% to -$88000.0 in 2022, then soared by 13478.41% to $11.8 million in 2023, then grew by 14.31% to $13.5 million in 2024, then skyrocketed by 199.03% to $40.2 million in 2025.
  • The last three reported values for Change in Receivables were $40.2 million (Q4 2025), $33.9 million (Q3 2025), and $41.4 million (Q2 2025) per Business Quant data.